MARKET

GNPX

GNPX

Genprex Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.79
+0.48
+8.99%
Opening 13:22 02/24 EST
OPEN
5.37
PREV CLOSE
5.31
HIGH
6.07
LOW
5.30
VOLUME
724.51K
TURNOVER
--
52 WEEK HIGH
7.72
52 WEEK LOW
1.490
MARKET CAP
273.60M
P/E (TTM)
-10.8397
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Genprex Shares Drop 15% After Securities Purchase Deals
Dow Jones · 02/09 18:40
Proactive news headlines including Tocvan Ventures, HempFusion Wellness, Milestone Scientific and Esports Entertainment Group
New York, Feb 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 09, 2021 (GLOBE NEWSWIRE) -- - Tocvan Ventures Corp (CSE:TOC) (FRA:TV3) says maiden...
GlobeNewswire · 02/09 16:04
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering
Feb 09, 2021 (Investor Brand Network via COMTEX) -- Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing...
Investor Brand Network · 02/09 15:28
DJ Genprex in Securities Purchase Deal for 4M Shares at $6.25/Shr
Dow Jones · 02/09 13:55
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Business Wire · 02/09 13:30
The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 9)
Benzinga · 02/09 13:10
Inspect the Fingerprints on the Genprex Offering, Before Making a Move
TheStreet.com · 02/09 12:27
Genprex announces formation of clinical advisory board
Genprex ([[GNPX]] +21.3%) announces the formation of a Clinical Advisory Board ((CAB)) to support its oncology and diabetes development programs.The CAB will lead and advise Genprex as it advances its REQORSA immunogene
Seekingalpha · 02/08 20:57
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GNPX. Analyze the recent business situations of Genprex Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GNPX stock price target is 6.67 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 81
Institutional Holdings: 7.12M
% Owned: 15.05%
Shares Outstanding: 47.28M
TypeInstitutionsShares
Increased
23
703.36K
New
15
1.42M
Decreased
9
115.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.29%
Pharmaceuticals & Medical Research
+1.34%
Key Executives
Chairman/President/Chief Executive Officer/Secretary/Director
J. Rodney Varner
Chief Financial Officer
Ryan Confer
Chief Operating Officer/Executive Vice President
Michael Redman
Executive Vice President
Catherine Vaczy
Independent Director
Brent Longnecker
Independent Director
Jose Moreno Toscano
Independent Director
William Wilson
Director
Will Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).

Webull offers kinds of Genprex Inc stock information, including NASDAQ:GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.